(+)-(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-ethanesulfonic acid | 479678-43-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (+)-(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-ethanesulfonic acid
• 英文别名: 2-[(1S,4R)-7,7-dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl]ethanesulfonic acid
• CAS: 479678-43-8
• 化学式: C₁₁H₁₈O₄S
• 分子量: 246.328
• InChiKey: DOSPHYGOXDFAJF-LDYMZIIASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  79.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (+)-(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-ethanesulfonic acid 在 ammonium hydroxide 、 氯化亚砜 作用下， 以 1,4-二氧六环 为溶剂， 反应 6.5h， 生成 (+)-(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-ethanesulfonamide
  参考文献：
  名称：

  Synthesis of a Six-Membered-Ring (2R)-10a-Homobornane-10a,2-sultam and Structural Comparison with Oppolzer's, Lang's, and King's Sultams

  摘要：

  The new six-membered-ring (2R)-10a-homobornane-10a,2-sultam (-)-3a was synthesized and its X-ray structural analysis was compared with that of the novel structure of the five-membered-ring (2R)-bornane-10,2-sultam analogues (-)-1a,b as well as with that already published for the six-membered-ring trans-decalin-like sultam 4a. Based on DN** density-function calculations and X-ray crystallographic studies of the N-methylated analogues (-)-1e and 4b and by comparing with the conformation of the N-fluoro derivatives (-)-1c and (+)-1d, the anomeric stabilization was estimated to be smaller than the 2.0-2.5 kcal/mol earlier suggested. The direction of pyramidalization is rationalized in terms of H-bond and steric and electronic interactions and extended to the known toluenesultam derivatives 10a-c.

  DOI：

  10.1002/1522-2675(200207)85:7<1973::aid-hlca1973>3.0.co;2-n
• 作为产物：
  描述：

  (-)-2-{(1S,4R)-7,7-dimethylspiro[bicyclo[2.2.1]heptane-2,2'-[1,3]dioxolan]-1-yl}ethyl ethanethioate 在 双氧水 作用下， 以 溶剂黄146 为溶剂， 反应 18.0h， 以92%的产率得到(+)-(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-ethanesulfonic acid
  参考文献：
  名称：

  Synthesis of a Six-Membered-Ring (2R)-10a-Homobornane-10a,2-sultam and Structural Comparison with Oppolzer's, Lang's, and King's Sultams

  摘要：

  The new six-membered-ring (2R)-10a-homobornane-10a,2-sultam (-)-3a was synthesized and its X-ray structural analysis was compared with that of the novel structure of the five-membered-ring (2R)-bornane-10,2-sultam analogues (-)-1a,b as well as with that already published for the six-membered-ring trans-decalin-like sultam 4a. Based on DN** density-function calculations and X-ray crystallographic studies of the N-methylated analogues (-)-1e and 4b and by comparing with the conformation of the N-fluoro derivatives (-)-1c and (+)-1d, the anomeric stabilization was estimated to be smaller than the 2.0-2.5 kcal/mol earlier suggested. The direction of pyramidalization is rationalized in terms of H-bond and steric and electronic interactions and extended to the known toluenesultam derivatives 10a-c.

  DOI：

  10.1002/1522-2675(200207)85:7<1973::aid-hlca1973>3.0.co;2-n

文献信息

• Process for making tetracyclic heterocycle compounds
  申请人：Merck Sharp & Dohme. Corp.

  公开号：US10202401B2

  公开（公告）日：2019-02-12

  The present invention is directed to a process for making Tetracyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2 and R3 are defined above herein. The present invention is also directed to compounds that may be useful as synthetic intermediates in the process of the invention.

  本发明涉及一种制造式（I）四环杂环化合物的工艺： 及其药学上可接受的盐类，其中 X1、X2、R1、R2 和 R3 的定义如上。本发明还涉及在本发明工艺中可用作合成中间体的化合物。
• COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
  申请人：AMGEN INC.

  公开号：US20170088560A1

  公开（公告）日：2017-03-30

  Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
• PROCESS FOR MAKING TETRACYCLIC HETEROCYCLE COMPOUNDS
  申请人：Merck Sharp & Dohme. Corp.

  公开号：US20180065985A1

  公开（公告）日：2018-03-08

  The present invention is directed to a process for making Tetracyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein X 1 , X 2 , R 1 , R 2 and R 3 are defined above herein. The present invention is also directed to compounds that may be useful as synthetic intermediates in the process of the invention.